share_log

Transcode Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Zdravka Medarova(0.4%)

SEC announcement ·  Feb 15 16:03
Summary by Moomoo AI
Zdravka Medarova, a United States citizen, has filed an amended Schedule 13G with the Securities and Exchange Commission (SEC) on December 31, 2023, disclosing her ownership in TransCode Therapeutics, Inc. The filing indicates that Medarova beneficially owns 112,077 shares of TransCode Therapeutics' common stock, which represents approximately 0.4% of the company's outstanding shares. This ownership includes 96,639 shares held directly and 15,438 shares issuable upon the exercise of stock options within 60 days of the reporting date. The filing also notes that these figures do not account for a 1-for-40 reverse stock split that occurred on January 16, 2024. The Schedule 13G amendment was submitted to report that Medarova now owns less than 5% of TransCode Therapeutics, as indicated by the checked box in Item 5 of the filing.
Zdravka Medarova, a United States citizen, has filed an amended Schedule 13G with the Securities and Exchange Commission (SEC) on December 31, 2023, disclosing her ownership in TransCode Therapeutics, Inc. The filing indicates that Medarova beneficially owns 112,077 shares of TransCode Therapeutics' common stock, which represents approximately 0.4% of the company's outstanding shares. This ownership includes 96,639 shares held directly and 15,438 shares issuable upon the exercise of stock options within 60 days of the reporting date. The filing also notes that these figures do not account for a 1-for-40 reverse stock split that occurred on January 16, 2024. The Schedule 13G amendment was submitted to report that Medarova now owns less than 5% of TransCode Therapeutics, as indicated by the checked box in Item 5 of the filing.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more